Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.
Min ST, Roohullah A, Tognela A, Jalali A, Lee M, Wong R, Shapiro J, Burge M, Yip D, Nott L, Zimet A, Lee B, Dean A, Steel S, Wong HL, Gibbs P, Lim SH. Min ST, et al. Among authors: shapiro j. Asia Pac J Clin Oncol. 2022 Apr;18(2):e56-e63. doi: 10.1111/ajco.13553. Epub 2021 Apr 18. Asia Pac J Clin Oncol. 2022. PMID: 33870631
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Mittmann N, et al. J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7. J Natl Cancer Inst. 2009. PMID: 19666851
Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Tang M, et al. Among authors: shapiro j. Expert Rev Anticancer Ther. 2018 Apr;18(4):339-349. doi: 10.1080/14737140.2018.1444481. Epub 2018 Mar 1. Expert Rev Anticancer Ther. 2018. PMID: 29478352 Review.
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
Burge M, Semira C, Lee B, Lee M, Kosmider S, Wong R, Shapiro J, Ma B, Dean AP, Zimet AS, Steel SA, Lok SW, Torres J, Eastgate M, Wong HL, Gibbs P. Burge M, et al. Among authors: shapiro j. Clin Colorectal Cancer. 2018 Sep;17(3):e593-e599. doi: 10.1016/j.clcc.2018.05.009. Epub 2018 Jun 1. Clin Colorectal Cancer. 2018. PMID: 29958812
Targeted therapy for metastatic colorectal cancer.
Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J. Price TJ, et al. Among authors: shapiro j. Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006. doi: 10.1080/14737140.2018.1502664. Epub 2018 Aug 3. Expert Rev Anticancer Ther. 2018. PMID: 30019590 Review.
The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, Yip D. Prasanna T, et al. Among authors: shapiro j. Acta Oncol. 2018 Nov;57(11):1438-1444. doi: 10.1080/0284186X.2018.1487581. Epub 2018 Jul 23. Acta Oncol. 2018. PMID: 30035653
2,592 results